UK food allergy diagnostic company, Reacta Biotech raises £1.25m to continue expansion plans
- Reacta Biotech raises £1.25m to secure MHRA site license
- Once achieved, the license will enable significantly expanded production of its Oral Food Challenge Diagnostic for food allergy
- Existing Investors Moulton Goodies Limited, Development Bank of Wales and Acceleris invest in this round
- Fundraising brokered by lead advisors, Acceleris Capital
Reacta Biotech has today announced the completion of its largest funding round to date, which has raised £1.25m of equity finance – with further investment expected in the coming months.
Reacta is a North-Wales based biotechnology company producing diagnostic kits for food allergy. Cases of food allergy and allergy related hospitalisations continue to rise globally at an alarming rate. Reacta’s core focus is to improve the diagnosis and management of allergies through the provision of a pharmaceutical grade Oral Food Challenge (“OFC”), the gold standard for the clinical testing of food allergy.
Current diagnostic methodologies for food allergies, including skin prick tests or measurement of specific IgE antibodies in blood samples, are innacurate. They yield many false positive results and provide no measure of severity of an allergic reaction. Oral Food Challenge is the gold standard forfood allergy diagnosis, before the initiation of new long term therapies, and for the assessment of treatment response.
The investment has been drawn down from existing investors, management, Moulton Goodies Limited, Development Bank of Wales and Acceleris Capital. The company has been advised by Acceleris Capital and Gateley.
The capital raised will be used to achieve the Medicines & Healthcare products Regulatory Agency (“MHRA”) approval of the Company’s manufacturing facility in Deeside, North Wales. Obtaining an MHRA site license (expected in the coming months) confers Pharma Good Manufacturing Practice (“GMP”) manufacturing status on Reacta, which, in turn, will allow the Company to begin production of larger volumes for product supply to highly regulated markets. By securing this license, the addressable market for the Company will be significantly expanded.
Professor Ashley Woodcock, Chairman of Reacta Biotech commented that, “This investment is a significant step in the development of Reacta Biotech’s business. A combination of seeking our own MHRA approval and the recent FDA approval of the first specific food allergy therapy set to launch in the US soon, creates ideal timing for Reacta to become the only standardised and trusted OFC for all food allergy therapeutics.”
Simon Thorn, MD of Acceleris said: “We are delighted to complete this transaction with the team at Reacta and the other existing shareholders. Reacta is on an upward curve and with the expected MHRA license, is in line to see significant expansion. This market has become increasingly apparent with the significant rise in global food allergy cases and the alarming increase in hospitalisations due to anaphylaxis. We are proud as a firm to work with such a leader in its field and a company that will make a huge difference to many peoples’ quality of life.”
Paul Abrahams, CEO of Reacta Biotech commented on the raise: “We are extremely pleased to announce our raise today and continue our positive progress towards becoming the only regulated oral food challenge diagnostic supplier in the market.”
“Our business is addressing a significant unmet need for standardised, stable, accurate, palatable and fully blinded OFC’s. Obtaining MHRA accreditation is a key driver for our future growth and we are pleased that we now have the investment to support the future demand for our regulated product and build on our revenues and list of customers.”
Michael Bakewell, Deputy Fund Manager who manages our technology venture investments at the Development Bank of Wales said: “We’re very happy to have been able to continue our support for Reacta Biotech with a further round of equity co-investment. This funding comes at a time when we are seeing a lot of global interest in food allergy therapeutics, an area where Reacta are fast making a name for themselves. Getting an MHRA site license for their Deeside manufacturing facility is a great next step in their growth as a company.”
About Reacta Biotech
Reacta’s goal is to improve the diagnosis and management of food allergy. This market need has become increasingly apparent with the substantial rise in global food allergy cases since the 1990’s. Alarmingly, during this period, there has been a 600% rise in hospitalisations due to anaphylaxis.
The Company’s initial focus is on peanut allergy, which is the most prevalent & severe global food allergy and is an area which has seen significant investment into the development of therapies.
About Acceleris Capital
Acceleris Capital is an FCA regulated corporate finance boutique which focuses on advising early-stage technology SMEs.
Since incorporation in 2000, Acceleris has advised and managed Latest Investments for over 50 UK businesses and raised over £120m, with a track record including start-up to IPO, trade sale and private equity exits.
Acceleris primarily source external funding directly from its network of High Net Worth investors and major UK investment institutions.
For more information and interviews, please contact:
Patrick Molyneux Acceleris Capital